A Phase 4 interventional study of Diclofenac and Celecoxib in Low Back Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 9 sites in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Low Back Pain with a site in Brazil — 10 open to participants now, 12 under way, none of them phase 3. Low Back Pain · Brazil.
Among the 125 studies in Low Back Pain with a site in Brazil, this one is the 8th largest by enrollment of the 122 interventional ones that give a count, is one of 2 that started in 2003, is one of 4 in phase 4, and was the 1st registered.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
Browse Low Back Pain studies →10 of the 125 studies in Low Back Pain with a site in Brazil are open now. Recruiting first, the newest first:
Federal University of Bahia · Sites in Brazil
Ages 18–55
Gabriela Souza de Vasconcelos · Sites in Brazil
Ages 18–59
University of Nove de Julho · Sites in Brazil
Ages 18–70
University of Nove de Julho · Sites in Brazil
Ages 18–65
Centro Universitário Augusto Motta · Sites in Brazil
Ages 65+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 12 · Phase 4 4
First in 2002; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 244 is above the median of 60 across 2,364 interventional studies indexed under Low Back Pain.
Median enrollment 66 across the 122 interventional studies, 100 across the 3 observational. Of the 75 that completed or were terminated, 5 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 8 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Low Back Pain with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05459376Universidade Federal do Rio Grande do NorteEffect of Dry Cupping Therapy Associated With the McKenzie Method in Patients With Chronic Low Back Pain | 2027-01-01 |
| NCT07639216Centro Universitário Augusto MottaNeuroscience Education and Spinal Manipulation on Health Locus of Control in Low Back Pain | 2027-07 |
| NCT05480982Centro Universitário Augusto MottaCognitive Functional Therapy Compared With Pilates in Elderly Patients With Chronic Low Back Pain | 2027-07 |
| NCT06651099University of BrasiliaTrial-based Economic Evaluation of a Mobile Health Intervention for Individuals With Chronic Non-specific Low Back Pain | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 125 studies in Low Back Pain with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of celecoxib versus sodium diclofenac in subjects with acute low back pain
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Diclofenac
Drug: Celecoxib
75 mg oral capsule twice daily for 7 days
400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
Change from baseline in patient-rated visual analogue scale (VAS) pain intensity assessment
Time frame: Day 3
Subject's quality of life, as measured by the SF-36 Health Survey
Time frame: Day 7
Physical examination
Time frame: Days 3 and 7
Pain relief score
Time frame: Days 3 and 7
Vital signs
Time frame: Days 3 and 7
Adverse events
Time frame: Days 3 and 7
Change from baseline in VAS pain intensity assessment
Time frame: Day 7
Categorical pain intensity score
Time frame: Days 3 and 7
Subject's global assessment score
Time frame: Days 3 and 7
Subject's functional ability, as measured by the "Roland Morris" Questionnaire about low back pain and disability
Time frame: Day 7
The record gives a start of Oct 2003 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →